

**P&T Motion History**  
**Diabetes Drugs – DPP-4 Inhibitors**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
alogliptin alogliptin + metformin alogliptin + pioglitazone linagliptin linagliptin + metformin linagliptin + metformin ER saxagliptin saxagliptin + metformin ER sitagliptin sitagliptin + metformin sitagliptin + metformin ER	<p>After considering the evidence of safety, efficacy and special populations for the treatment of diabetes, I move that DPP-4 inhibitors linagliptin, saxagliptin, alogliptin, sitagliptin and all listed combination drugs in this sub-class are safe and efficacious.</p> <p>DPP-4 inhibitors can be subject to therapeutic interchange in the Washington preferred drug list.            Therapeutic interchange is allowed only within each diabetes sub-class.</p> <p>Motion: Figueroa            2<sup>nd</sup>: Lee</p>	June 15, 2022	Yes Schwilke Park	Yes Chawla Corsilles	Passed unanimous